ear Readers, dear Business Associates, when developing machines and processes for our customers' products, risk minimization is our top priority. But when it comes to questioning the familiar and exploring new horizons, we do not shy away from the risk. Whether it is the optimization of products, devices and processes, or the development of brand-new technologies: Our experts are clearly at the forefront.

For years, for instance, worldwide research has been conducted on how vaccination campaigns in developing countries can be simplified. Microneedle patches could be a key to the solution, according to the World Health Organization (WHO). As an example, we are currently working with the start-up company VAXXAS to pave the way for this future technology to reach affordable large-scale production.

Good is not good enough – that is what spurs on our specialists in Engineering & Innovation Services. With the help of an innovative method for water sealing, they have not only succeeded in tightly joining water-soluble films. They have succeeded in optimizing impermeability and improving the safety of the packages.

We also look for ways to make the manufacturing process for your product safer and more scalable: With the expansion of our cleanrooms for trials, verification and process creation, we reduce risks. The enlargement of our laboratory space allows us to assist you as early as the formulation development phase. Using state-of-the-art equipment and high-level safety standards, we manifest our holistic "From Lab to Production" approach.

About 20 years ago we were the first machine manufacturer with in-house cleanrooms. This investment risk paid off a long time ago, and it will pay off this time: With added safety for our employees, better verification of process parameters, and with your confidence in our technology and expertise.

Yours,

Thomas Weller, CEO at Harro Höfliger

